BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The aim of this study is to demonstrate if it is possible to delivering a novel and modern radiotherapy approach (Dose Escalated internal PTV (DE-iPTV)) and to collect health related quality of life in patients whose breast cancer has spread to the brain (brain metastases) at 8 weeks post enrolling into the study. The main questions that have been set out to to answer are: * Is it possible to deliver the novel radiotherapy approach, DE-iPTV? * Is it possible to measure health -related quality of life? * What impact does the novel radiotherapy approach have on: patient's quality of life, control of the brain metastasis (control of the lesion) and steroid use? Participants will: * Receive 5 doses of radiotherapy * Complete weekly quality of life (EQ-5D) assessments and medication (steroid) diaries (via telephone/ postal) until 12 weeks post enrolment * Be reviewed in clinic with up-to-date MRI scans at 8, 12 and 24 weeks post-enrolment * Complete a more detailed HRQoL panel of assessments will be assessed at baseline, 8 weeks, 12 weeks and 24 weeks post enrolment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 16 lat lub więcej
- •Potwierdzony histologicznie rak piersi z przerzutami do mózgu widocznymi w badaniu MRI
- •Ogólny stan zdrowia oceniony na 0-2 w skali ECOG (pacjent może wykonywać codzienne czynności)
- •Możliwość odpowiadania na pytania o jakość życia przez telefon lub pocztę
- •Spodziewana długość życia z powodu choroby poza mózgiem dłuższa niż 3 miesiące
- •Podpisana świadoma zgoda na uczestnictwo w badaniu
✗ Disqualifies
- •Nowotwór rozprzestrzenił się na opony mózgowe
- •Ponad 15 przerzutów w mózgu
- •Wcześniejsza radioterapia całego lub części mózgu
- •Ciąża lub karmienie piersią
- •Niemożność wykonania badania MRI mózgu lub uczulenie na gadolin
- •Spodziewana długość życia poniżej 3 miesięcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 16 Years
- Maximum age
- 100 Years
- Last updated (source)
- October 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Imperial College London
London, United Kingdom
University of Oxford Cancer and Haematology Centre | Churchill Hospital Headington, Oxford,
Oxford, United Kingdom
Trial contact
Lillie Pakzad-Shahabi, BSc MSc
Matt Williams, FRCR PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.